Khaitan & Co, TT&A and Hogan Lovells advise on Symbiotec Pharmalab’s proposed ₹21,800 million IPO.
The proposed offering comprises a fresh issue of ₹1,500 million and an offer for sale of ₹20,300 million by certain existing shareholders of the company.
Khaitan & Co advised Symbiotec Pharmalab Pvt. Ltd. On the filing of its Draft Red Herring Prospectus (DRHP) for its proposed initial public offering.
The deal team included Gautham Srinivas, Sathvik Ponnappa, Pulkit Singh Rahangdale, Anubhav Jaiswal, Sarvesh Sharma, Dharini Shanker, Anushaka Sharma, Swadha Swaroop and Naman Seth.
Talwar Thakore & Associates (TT&A) is advising the book running lead managers—JM Financial Ltd, Avendus Capital, Motilal Oswal Investment Advisors Limited and Nomura Financial Advisory and Securities (India) Private Limited on the IPO.
The team was led by Partner Abhinav Kumar, Managing Associate Shubham Sancheti, Associates Abhishek Iyer, Daniyal Khan, Akshita Sharma, Harsh Shekhar, and Jahnavi Seethamraju.
Hogan Lovells served as the international legal counsel to the BRLMs on this IPO.
The transaction team was led by Head of India Practice and Dubai Office Managing Partner Biswajit Chatterjee.
The deal reporting on this platform is based on the information received from law firms, and therefore, some details may be missing/incomplete. If your firm has not been credited for this deal, write to us at chanchal.makhija@thegreymatter.co.in mentioning your firm’s name, lawyers involved (including designation) and client represented.
